Skip to content

Author

Md. Nazim Uddin

We have 3 of 30 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Finding Novel Inhibitors of FMS-like Tyrosine Kinase 3 from Selected FDA-approved Anticancer Drugs: Insights from Molecular Docking, MD Simulations, and ADMET Profiling.

BACKGROUND Wild-type FLT3 (WT-FLT3) has emerged as a relevant molecular target in Acute Myeloid Leukemia (AML), with increasing evidence implicating its role in leukemic proliferation and resistance, even in the absence of FLT3 mutations. Although gilteritinib is an approved FLT3 inhibitor, its efficacy in WT-FLT3 AML...

Mohammed H. al Mughram, L. J. Babatola, Md. Nazim Uddin et al. · 0 citations
Open access Oct 2026

Identification of potential breast cancer therapeutics from non-phenolic diarylheptanoids of Curcuma xanthorrhiza using network pharmacology and in silico methods

Curcuma xanthorrhiza, a widely recognized medicinal plant, contains three non-phenolic diarylheptanoids (NPDs) that exhibit diverse biological properties. Despite their known bioactivities, the precise molecular mechanisms underlying their therapeutic potential, particularly in breast cancer (BRCA) treatment, remain la...

Roney Miah, Md. Nazim Uddin, Md Mahfuz Miah et al. · 0 citations
Sep 2026

Molecular Docking and Dynamics Analyses for Evaluation of Interactions Between the Human Receptor and Viral Proteins of Enterovirus A71

Interactions between EV‐A71 proteins and the human receptor SCARB2 and the human receptor SCARB2 using molecular docking and molecular dynamics simulations under balanced, electrostatic, hydrophobic, and VdW+Elec conditions are examined to reveal key EV‐A71–SCARB2 interaction mechanisms.

Roney Miah, Md. Nazim Uddin, Muhammad Nuh et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.